Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
SearchAbout VELSIPITYAbout VELSIPITYUncontrolled DiseasePatient ProfilesVELSIPITY OverviewMOAEfficacyEfficacyTrial DesignEfficacy DataSafetySafetyELEVATE UCENLIGHT UCStarting TreatmentAccess & SupportAccess & SupportVelsipityForMe Patient SupportEnrollment ResourcesResourcesResourcesRequest a RepEventsMaterialsVideos
Prescribing InformationMedication GuideIndication Patient SiteRequest Samples
VELSIPITY insurance coverage is expanding! To learn more, ask your Pfizer representative.

Access & Support

Access & Support

VelsipityForMe offers support and savings to help eligible patients get started on their medication

Dedicated Care Coordinators

Health Screening Support

The Dedicated Care Coordinator will be a consistent, primary point of contact to:

The Dedicated Care Coordinator will be a consistent, primary point of contact to:
  • Welcome enrolled patients into the program*
  • Explain insurance coverage and identify potential financial assistance options
  • Schedule health screenings for eligible, commercially insured patients† 
  • Communicate patient status
ReferencesPatients are typically welcomed within one business day of enrollment or the following Monday if enrollment takes place on a Friday. Response times may vary per individual case.For commercially insured patients only who do not reside in MI, MN, or RI.

VelsipityForMe offers support for eligible, commercially insured patients for health screenings completed at the patient’s home or provider’s office

Prior to treatment complete:
 Prior to treatment complete:At-home assessment*

VelsipityForMe can arrange for a licensed clinician to visit your patient's home to perform the following, based on testing needs

 Complete blood count with differential 

 Liver function tests

 Varicella-zoster virus serology, if required 

In-office assessment

For patients whose assessments are completed at a provider's office

 Reimbursement for qualified OOP expenses† 

At-home assessment*

VelsipityForMe can arrange for a licensed clinician to visit your patient's home to perform the following, based on testing needs

 Baseline ECG
  • If only requesting ECG, a device can be shipped to patient's home with step-by-step instructions‡
 ECG test results will be interpreted by a cardiologist and typically shared back with the HCP office within 3 business days
In-office assessment

For patients whose assessments are completed at a provider's office

 Overread by a cardiologist is available for ECGs that were conducted in office

 Reimbursement for qualified OOP expenses†

Shortly after the start of treatment, or right before:
 Shortly after the start of treatment, or right before:At-home assessment*

VelsipityForMe can arrange for a licensed clinician to visit your patient's home† to perform the following, based on testing needs

 Ophthalmic scan will not require dilation or puff of air
  • The ophthalmic exam takes approximately 3-5 minutes to complete
  • The results will be interpreted by an ophthalmologist
In-office assessment

For patients whose assessments are completed at a provider's office

 Support scheduling near-term appointments at a provider's office*

 Eligible patients may be reimbursed up to $2,500 for qualified out-of-pocket expenses related to health screenings completed at a provider’s office†

In-office assessment

For patients whose assessments are completed at a provider's office

 Support scheduling near-term appointments at a provider's office*

 Eligible patients may be reimbursed up to $2,500 for qualified out-of-pocket expenses related to health screenings completed at a provider’s office†

ReferencesHealth screening coordination services are not available for patients enrolled in a state or federally funded health insurance program, or patients who reside in MI, MN, or RI.Eligibility required. Not available for patients enrolled in a state or federally funded health insurance program, or patients who reside in MI, MN, or RI.Virtual assistance is available if needed. The VELSIPITY ECG Interpretation Program is only available to patients if an ECG has been previously conducted within 6 months of the request for service.ECG=electrocardiogram; OOP=out of pocket.NOTE: Remember that a review of medication history and vaccinations is also required prior to the start of treatment*Health screening coordination services are not available for patients enrolled in a state or federally funded health insurance program, or patients who reside in MI, MN, or RI.
†Eligibility required. Not available for patients enrolled in a state or federally funded health insurance program, or patients who reside in MI, MN, or RI.
‡Virtual assistance is available if needed. The VELSIPITY ECG Interpretation Program is only available to patients if an ECG has been previously conducted within 6 months of the request for service.ECG=electrocardiogram; OOP=out of pocket.NOTE: Remember that a review of medication history and vaccinations is also required prior to the start of treatment

Additional offerings for your patients

Support Getting Started

Reimbursement Support

Additional Support

VelsipityForMe is committed to helping eligible patients receive their VELSIPITY treatmentVoucher Rx A free, one-time, 30-day trial for new patients to get started. Terms and Conditions apply. Interim Care Rx (Bridge Program) Up to 2 years of VELSIPITY at no cost shipped through Interim Care Rx (Bridge Program) for eligible, commercially insured patients enrolled in VelsipityForMe who experience a delay or denial of coverage during the prior authorization or appeals process. Terms and Conditions apply.



 
Up to 2 years of VELSIPITY at no cost shipped through Interim Care Rx for eligible, commercially insured patients enrolled in VelsipityForMe who experience a delay or denial of coverage during the prior authorization or appeals process. Terms and Conditions apply.The free product for this program is only for certain commercially insured patients. Terms and Conditions apply. Not available to residents in the states of MA or MI. For residents of MN or RI, it is available for up to six months. Copay Savings Program
Patients could pay as little as $0 in out-of-pocket costs, with a maximum prescription benefit of $16,000 per calendar year with the Copay Savings Program. For eligible, commercially insured patients only. Terms and Conditions apply.
Enroll Your Patient
LoadingEligibility required. Commercially insured patients only. The maximum prescription benefit offer per patient is $4,000 to $16,000 per calendar year. Patients enrolled in a state or federally funded prescription health insurance program are not eligible. No membership fees. This is not health insurance. Available only to patients who have been diagnosed with an FDA-approved indication for VELSIPITY.

From benefits verification to appeals assistance, VelsipityForMe helps navigate the insurance process

Assistance With Benefits Investigation
  • Investigate and assess your patient’s insurance benefits and coverage determinations
  • Communicate the Summary of Benefits to patients and caregivers
Prior Authorization (PA) Assistance
  • VelsipityForMe can provide Payers' PA form, if available
Appeals Assistance
  • Provide information regarding the necessary forms, phone numbers, and contact details for patients who would like to appeal a PA denial​​

From benefits verification to appeals assistance, VelsipityForMe helps navigate the insurance process

From benefits verification to appeals assistance, VelsipityForMe helps navigate the insurance process

 Government-Funded Insurance

For those patients who need help with their medication cost-sharing requirements, VelsipityForMe can refer patients who appear to be eligible for Medicare Extra Help.











For those patients who need help with their medication cost-sharing requirements, VelsipityForMe can refer patients who appear to be eligible for Medicare Extra Help.

 No Insurance or Underinsured
For those patients who need financial assistance, VelsipityForMe can refer your patient to Medicaid if your patient appears to be eligible. If turned down, VelsipityForMe can evaluate your patient for the Pfizer Patient Assistance Program.

Pfizer Patient Assistance Program*—Eligible patients may receive VELSIPITY at no charge. Terms and Conditions apply.
*The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. Free medicines from Pfizer are provided through the Pfizer Patient Assistance Foundation. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
Access & Support
Enroll your patients online to connect them with support—no printing or faxing required.
Questions? Call 1-800-350-3080 (Monday-Friday, 8 AM-8 PM ET).
Discover VelsipityForMe, the patient support program for VELSIPITY.Watch the Video Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-V1A-USA-1751
IndicationVELSIPITY® (etrasimod) is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
Important Safety Information Contraindications
  • Patients in the last 6 months who experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure
  • Patients with a history or presence of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
Infections 

VELSIPITY may increase the susceptibility to infections. Life-threatening and rare fatal infections have been reported in association with other sphingosine 1-phosphate (S1P) receptor modulators. Before starting VELSIPITY, obtain a recent (i.e., within 6 months) CBC, including lymphocyte count. Delay initiation of VELSIPITY in patients with an active infection until the infection is resolved. Consider interruption of treatment with VELSIPITY if a patient develops a serious infection. Continue monitoring for infections up to 5 weeks after discontinuing VELSIPITY.

  • Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain that typically occurs in patients who are immunocompromised, and usually leads to death or severe disability. PML has been reported in multiple sclerosis (MS) patients treated with S1P receptor modulators and has been associated with risk factors and duration of use. Longer treatment duration (≥18 months) increases the risk of PML. VELSIPITY is not indicated in MS. If PML is suspected, suspend VELSIPITY and discontinue if PML is confirmed by appropriate diagnostic evaluation. Immune reconstitution inflammatory syndrome (IRIS) has been reported in patients with MS treated with S1P receptor modulators who developed PML and discontinued treatment. Clinical decline may be rapid, can lead to serious neurological complications or death, and is often associated with characteristic MRI changes. Onset was generally within a few months after S1P receptor modulator discontinuation. Monitoring for IRIS should be undertaken.
  • Herpes simplex encephalitis, varicella zoster meningitis, and localized herpes viral infections have been reported with S1P receptor modulators. In UC-1, herpes zoster was reported in 0.7% of subjects treated with VELSIPITY and in none of the subjects who received placebo. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating VELSIPITY. A full course of VZV vaccination for antibody-negative patients is recommended prior to commencing treatment with VELSIPITY.
  • Cases of fatal cryptococcal meningitis (CM) and disseminated cryptococcal infections have been reported with S1P receptor modulators. VELSIPITY treatment should be suspended until a cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.
  • VELSIPITY has not been studied in combination with anti-neoplastic, immune-modulating, or non-corticosteroid immunosuppressive therapies. Avoid concomitant administration of these therapies with VELSIPITY. 
  • Update immunizations according to current guidelines prior to VELSIPITY treatment. Avoid the use of live attenuated vaccines during and for 5 weeks after treatment with VELSIPITY. If live attenuated vaccine immunizations are required, administer at least 4 weeks prior to initiation of VELSIPITY.
Bradyarrhythmia and Atrioventricular (AV) Conduction Delays
Initiation of VELSIPITY may result in a transient decrease in heart rate and AV conduction delays. Before starting VELSIPITY, obtain an ECG to assess for preexisting cardiac conduction abnormalities. Seek advice of a cardiologist for patients with: significant QT prolongation; arrhythmia requiring treatment with Class Ia or Class III anti-arrhythmic drugs or QT prolonging drugs; unstable ischemic heart disease, Class I or Class II heart failure, history of cardiac arrest, cerebrovascular disease, or uncontrolled hypertension; resting HR<50bpm; history of symptomatic bradycardia, recurrent cardiogenic syncope, or severe untreated sleep apnea; history of Mobitz type I second-degree AV block in the absence of a functioning pacemaker.

Liver Injury
Elevations of aminotransferases may occur in patients receiving VELSIPITY. Obtain transaminase and bilirubin levels, if not recently available (i.e., within the last 6 months), before initiation of VELSIPITY or in patients who develop symptoms suggestive of hepatic dysfunction. Discontinue VELSIPITY if significant liver injury is confirmed. Use of VELSIPITY in patients with severe hepatic impairment is not recommended.

Macular Edema
S1P receptor modulators have been associated with an increased risk of macular edema. Obtain baseline evaluation of the fundus, including the macula near the start of VELSIPITY treatment. Periodically assess the fundus, including the macula, during treatment or if there is a change in vision. Consider discontinuing VELSIPITY if macular edema develops. 

Increased Blood Pressure 
VELSIPITY patients in clinical trials had average increases of 1 to 4 mm Hg systolic and 1 to 2 mm Hg diastolic blood pressure (BP). Increases were first detected after 2 weeks of treatment and remained within the specified average range of BP increases throughout treatment. Monitor BP during treatment with VELSIPITY and manage appropriately.

Fetal Risk
Based on animal studies, VELSIPITY may cause fetal harm. Advise pregnant females and females of reproductive potential of the potential risk to a fetus and to use effective contraception to avoid pregnancy during and for one week after stopping VELSIPITY. Pregnant females exposed to VELSIPITY are encouraged to contact the pregnancy registry by calling 1-800-616-3791.

Cutaneous Malignancies
Risk of cutaneous malignancies is increased in patients treated with S1P receptor modulators in clinical trials and cutaneous malignancies have been reported in the postmarketing setting. Skin examinations are recommended prior to or shortly after the start of treatment and periodically thereafter for all patients, particularly those with risk factors for skin cancer. Monitor for suspicious skin lesions. Limit UV exposure including phototherapy.

Posterior Reversible Encephalopathy Syndrome
Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported in patients receiving S1P receptor modulators. If a patient develops neurological or psychiatric symptoms/signs or any symptom/sign suggestive of an increase of intracranial pressure, or accelerated neurological deterioration, complete a physical and neurological examination promptly and consider an MRI. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, discontinue treatment with VELSIPITY.

Respiratory Effects
VELSIPITY may cause a decline in pulmonary function. Spirometric evaluation should be conducted during therapy if clinically indicated.

Unintended Additive Immune System Effects from Prior Treatment with Immunosuppressive or Immune-Modulating Drugs
When switching to VELSIPITY from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.

Immune System Effects After Stopping VELSIPITY
After stopping VELSIPITY, lymphocyte counts returned to the normal range in 90% of subjects within 4 to 5 weeks. Use of immunosuppressants within this period may lead to an additive effect on the immune system, and therefore monitor patients receiving concomitant immunosuppressants for infectious complications up to 5 weeks after the last dose of VELSIPITY.

Most Common Adverse Reactions
Most common adverse reactions reported in ≥ 2% of subjects and at a higher rate than placebo included: headache, elevated liver tests, dizziness, arthralgia, nausea, hypertension, bradycardia, UTI, hypercholesterolemia, and herpes viral infection.

Please see full Prescribing Information, including Medication Guide.Indication

VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.